aTyr Pharma presents three posters on efzofitimod at ATS 2025 Conference

aTyr Pharma (ATYR) announced three poster presentations for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society 2025 International Conference, which is being held May 16 – 21, 2025, in San Francisco, CA. Title: Real-World Treatment Patterns Among Pulmonary Sarcoidosis Patients with Parenchymal Involvement in the US: Treatments used in real-world clinical management for pulmonary sarcoidosis patients with parenchymal involvement in the U.S. were evaluated using claims databases. Key data include: Glucocorticoids remain the most common treatment, with usage rates higher than previously reported; Most patients on second-line advanced therapies continue glucocorticoid use, highlighting challenges with tapering despite safety concerns and treatment guidelines; Treatment intensity escalates over time, with patients progressing rapidly to later-line therapies;10% of non-incident patients required high-cost, off-label biologics within three years. Title: EFZO-FIT, the Largest Placebo-Controlled Trial in Pulmonary Sarcoidosis: The poster describes the Phase 3 EFZO-FIT study design and includes blinded baseline demographics and disease characteristics: 268 patients enrolled; 264 dosed and included in the analysis; Patient population consistent with moderate to severe chronic symptomatic pulmonary sarcoidosis; Mean baseline oral corticosteroid dose was 10.55 mg; 38.3% of patients were on steroid-sparing immunosuppressants at baseline; Four unblinded data and safety monitoring board reviews recommended the continuation of the trial without modification, citing no undue safety risk. Title: Incidence, Prevalence, and Mortality of Pulmonary Sarcoidosis with Parenchymal Involvement in the US: Epidemiology and longitudinal analyses were conducted to assess incidence, prevalence, mortality and hospitalization rates of pulmonary sarcoidosis patients with parenchymal involvement in the U.S. Key data found: Approximately 158,900 people in the U.S. have pulmonary sarcoidosis with parenchymal involvement; An estimated 30,000 new cases diagnosed annually; The disease disproportionately affects women and Black individuals; 1 in 8 patients are hospitalized within 3 years; average stay greater than 5 days; 40% of patients are over age 65; Mortality among patients aged 65-74 is nearly double that of general population.